Weight-loss drug semaglutide does not slow Alzheimer's disease, two clinical trials find

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer’s disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.

Continue Reading

News Source: medicalxpress.com